Skip to main content
OpenTrials
Completed

NCT Number: NCT01751516

PET/MRI as a Predictor of Response to Pre-op Chemoradiation in Resectable Rectal Cancer: a Pilot Study

This is a single arm, single center pilot study of 40 patients with uT3N0 or uT1-3N+ rectal cancer receiving pre-operative chemoradiation. Subjects will undergo PET/MRI scans before and after surgery.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

University of North Carolina-Chapel Hill

Chapel Hill, North Carolina, 27599, United States

About this study

The primary purpose of this study is to determine the negative predictive value of PET/MRI for determining pathological complete response from neoadjuvant chemoradiation.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Low-lying, low- to moderate-risk pathologically-confirmed rectal cancer (stage uT3n) or uT1-3N+
  • Negative workup for distant disease
  • > 18 years of age
  • Pre-treatment workup completed including:
  • history and physical
  • CT or MRI of the abdomen and pelvis
  • endoscopic tumor evaluation (biopsy, blood work to assess CEA and hematopoietic, renal and liver function)
  • if female of child-bearing age, negative pregnancy test
  • Recommendation to undergo preoperative concurrent chemoradiation, as determined by the treating physician
  • Informed consent reviewed and signed

Exclusion criteria

  • Not deemed a candidate for preoperative chemoradiation for medical reasons, such as uncontrolled infection (including HIV), uncontrolled diabetes mellitus or cardiac disease
  • Hemoglobin ≤ 10.0 g/dL (transfusion allowed to achieve or maintain levels)
  • ANC ≤ 1,500/cubic mm³
  • Platelet count ≤ 100,000/mm³
  • ALT and AST ≥ 2.5 times upper level of normal (ULN)
  • Alkaline phosphatase ≥ 2.5 times ULN
  • Total bilirubin ≥ 1.5 times ULN
  • Creatinine clearance < 50 mL/min
  • Creatinine ≥ 1.5 times ULN
  • Not deemed a candidate for concurrent preoperative chemoradiation for social reasons, such as psychiatric illness
  • Not deemed a surgical candidate
  • Currently active second malignancy, except non-melanoma skin cancer, non-invasive bladder cancer, low risk adenocarcinoma of the prostate and carcinoma in situ of the cervix
  • Previous pelvic radiation therapy
  • History of severe reaction to gadolinium
  • Inability to tolerate MRI (e.g., inability to lie flat for > 1 hour)
  • Presence of a pacemaker, intracranial aneurysm clip, bladder stimulator, cochlear implant or metal near eyes
  • Body Mass Index (BMI) > 35
  • Pregnant or lactating female

Treatment and study plan

Primary outcomes

  1. Negative post-chemoradiation PET/MRI scan, as correlated with surgical pathology

    Time frame: 4-8 weeks post-chemoradiation

Secondary outcomes

  1. Recurrence-free survival

    Time frame: 5 years

  2. Disease-specific survival

    Time frame: 5 years

  3. Overall survival

    Time frame: 5 years

Sponsors and collaborators

Lead sponsor

UNC Lineberger Comprehensive Cancer Center

Other

Registry information

Official study title

PET/MRI as a Predictor for Response to Preoperative Radiation Therapy and Chemotherapy in Resectable Rectal Cancer: a Pilot Study.

Important dates

Study start
2012
Primary completion
2014
Study completion
2018
First posted
Dec 18, 2012
Registry last updated
Jan 29, 2021

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.